Skip to main content
RPbio Inc. logo

RPbio Inc. — Investor Relations & Filings

Ticker · 314140 ISIN · KR7314140005 KO Manufacturing
Open in API
Filings indexed 93 across all filing types
Latest filing 2024-03-19 AGM Information
Country KR South Korea
Listing KO 314140

About RPbio Inc.

https://rpbio.co.kr/html/en/main.php

RPbio Inc. is a bio-health company specializing in the development and production of pharmaceuticals and health functional foods. Established in 1983 as a joint venture with RP Scherer, the company is a leading producer of soft capsules, leveraging extensive technological expertise. RPbio operates as a Contract Development and Manufacturing Organization (CDMO), providing comprehensive services that include research and development, raw material sourcing, manufacturing of finished drugs, and OEM/ODM for health supplements. The company focuses on advancing softgel technologies and offers integrated solutions, including regulatory support, to its global partners in the pharmaceutical and health sectors.

Recent filings

Filing Released Lang Actions
[기재정정]주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Convocation of the Annual General Meeting' (주주총회소집공고) for RP Bio. It contains the agenda for the upcoming AGM, including financial statement approval, dividend proposals, director appointments, and remuneration limits. It also includes detailed financial tables (balance sheet, income statement, etc.) as part of the management's reference materials for the meeting. This is a standard proxy statement/information circular provided to shareholders prior to an AGM, which falls under the 'Proxy Solicitation & Information Statement' category.
2024-03-19 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Alpi Bio regarding a decision on cash dividends. It specifies the dividend amount per share, the dividend record date, the payment date, and the approval process via the general meeting of shareholders. This aligns perfectly with the definition of a 'Notice of Dividend Amount' (DIV).
2024-03-14 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for the company 'Alpibio'. It outlines the date, location, agenda items (including financial statement approval, dividend approval, and director appointments), and board resolution details. This type of document is a standard proxy solicitation and information statement provided to shareholders to inform them of upcoming meeting details and agenda items, which falls under the 'Proxy Solicitation & Information Statement' category.
2024-03-14 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for RP Bio. It contains the agenda for the upcoming Annual General Meeting (AGM), including items such as financial statement approval, dividend declarations, and director appointments. It also includes management information and proxy-related details. According to the filing definitions, documents providing information and requesting votes for meetings are classified as Proxy Solicitation & Information Statement (PSI).
2024-03-14 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company (RP Bio) is holding its meeting on a date that coincides with many other companies' meetings, citing audit and preparation timelines. Since this is a specific regulatory disclosure regarding meeting logistics rather than the meeting materials themselves or a proxy statement, it falls under the general regulatory filing category.
2024-03-14 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Alpi Bio) announcing a significant change (over 15% or 30%) in revenue or profit structure. This is a standard regulatory disclosure requirement in the Korean market (DART system) for public companies to report preliminary financial results before the final audit is completed. Since it provides key financial highlights and performance metrics rather than a full annual report or a simple publication notice, it falls under the Earnings Release (ER) category. FY 2023
2024-02-15 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.